Literature DB >> 12468568

AVE 0991, a nonpeptide mimic of the effects of angiotensin-(1-7) on the endothelium.

Gabriele Wiemer1, Lawrence W Dobrucki, Febee R Louka, Tadeusz Malinski, Holger Heitsch.   

Abstract

Recently, we demonstrated that the heptapeptide angiotensin-(1-7) (Ang-[1-7]) exhibits a favorable kinetic of nitric oxide (NO) release accompanied by extremely low superoxide (O2-) production. In this report we describe AVE 0991, a novel nonpeptide compound that evoked effects similar to Ang-(1-7) on the endothelium. AVE 0991 and unlabeled Ang-(1-7) competed for high-affinity binding of [125I]-Ang-(1-7) to bovine aortic endothelial cell membranes with IC50 values of 21+/-35 and 220+/-280 nmol/L, respectively. Stimulated NO and O2- release from bovine aortic endothelial cells was directly and simultaneously measured on the cell surface by selective electrochemical nanosensors. Peak concentrations of NO and O2- release by AVE 0991 and Ang-(1-7) (both 10 micromol/L) were not significantly different (NO: 295+/-20 and 270+/-25 nmol/L; O2-: 18+/-2 and 20+/-4 nmol/L). However, the released amount of bioactive NO was approximately 5 times higher for AVE 0991 in comparison to Ang-(1-7). The selective Ang-(1-7) antagonist [D-Ala(7)]-Ang-(1-7) inhibited the AVE 0991-induced NO and O2- production by approximately 50%. A similar inhibition level was observed for the Ang II AT1 receptor antagonist EXP 3174. In contrast, the Ang II AT2 receptor antagonist PD 123,177 inhibited the AVE 0991-stimulated NO production by approximately 90% but without any inhibitory effect on O2- production. Both NO and O2- production were inhibited by NO synthase inhibition ( approximately 70%) and by bradykinin B2 receptor blockade (approximately 80%). AVE 0991 efficiently mimics the effects of Ang-(1-7) on the endothelium, most probably through stimulation of a specific, endothelial Ang-(1-7)-sensitive binding site causing kinin-mediated activation of endothelial NO synthase.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12468568     DOI: 10.1161/01.hyp.0000037979.53963.8f

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  60 in total

Review 1.  Role of ACE2 in diastolic and systolic heart failure.

Authors:  Wang Wang; Sreedhar Bodiga; Subhash K Das; Jennifer Lo; Vaibhav Patel; Gavin Y Oudit
Journal:  Heart Fail Rev       Date:  2012-09       Impact factor: 4.214

Review 2.  International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected].

Authors:  Sadashiva S Karnik; Hamiyet Unal; Jacqueline R Kemp; Kalyan C Tirupula; Satoru Eguchi; Patrick M L Vanderheyden; Walter G Thomas
Journal:  Pharmacol Rev       Date:  2015-10       Impact factor: 25.468

Review 3.  Fetal programming and the angiotensin-(1-7) axis: a review of the experimental and clinical data.

Authors:  Andrew M South; Hossam A Shaltout; Lisa K Washburn; Alexa S Hendricks; Debra I Diz; Mark C Chappell
Journal:  Clin Sci (Lond)       Date:  2019-01-08       Impact factor: 6.124

Review 4.  The vasoprotective axes of the renin-angiotensin system: Physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases.

Authors:  Xiao C Li; Jianfeng Zhang; Jia L Zhuo
Journal:  Pharmacol Res       Date:  2017-06-12       Impact factor: 7.658

Review 5.  Significance of angiotensin 1-7 coupling with MAS1 receptor and other GPCRs to the renin-angiotensin system: IUPHAR Review 22.

Authors:  Sadashiva S Karnik; Khuraijam Dhanachandra Singh; Kalyan Tirupula; Hamiyet Unal
Journal:  Br J Pharmacol       Date:  2017-03-09       Impact factor: 8.739

6.  The nonpeptide AVE0991 attenuates myocardial hypertrophy as induced by angiotensin II through downregulation of transforming growth factor-beta1/Smad2 expression.

Authors:  Jian-Gui He; Sheng-Long Chen; Yi-Yi Huang; Yi-Li Chen; Yu-Gang Dong; Hong Ma
Journal:  Heart Vessels       Date:  2010-07-31       Impact factor: 2.037

Review 7.  New agents modulating the renin-angiotensin-aldosterone system-Will there be a new therapeutic option?

Authors:  Anna Gromotowicz-Poplawska; Piotr Szoka; Patrycjusz Kolodziejczyk; Karol Kramkowski; Marzena Wojewodzka-Zelezniakowicz; Ewa Chabielska
Journal:  Exp Biol Med (Maywood)       Date:  2016-07-19

8.  Cellular basis of angiotensin-(1-7)-induced augmentation of left ventricular functional performance in heart failure.

Authors:  Xiaowei Zhang; Heng-Jie Cheng; Peng Zhou; Dalane W Kitzman; Carlos M Ferrario; Wei-Min Li; Che Ping Cheng
Journal:  Int J Cardiol       Date:  2017-01-10       Impact factor: 4.164

Review 9.  ACE2, angiotensin-(1-7) and Mas receptor axis in inflammation and fibrosis.

Authors:  A C Simões e Silva; K D Silveira; A J Ferreira; M M Teixeira
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

Review 10.  The sweeter side of ACE2: physiological evidence for a role in diabetes.

Authors:  Sharell M Bindom; Eric Lazartigues
Journal:  Mol Cell Endocrinol       Date:  2008-10-01       Impact factor: 4.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.